AROCELL AB (PUBL) Inactive Instrument
AroCell AB (publ) Share Price Nasdaq Stockholm
Equities
SE0003883990
Biotechnology & Medical Research
| Sales 2024 * | 61M 5.58M 446M | Sales 2025 * | 82.4M 7.53M 603M | Capitalization | 85.69M 7.83M 627M |
|---|---|---|---|---|---|
| Net income 2024 * | -51M -4.66M -373M | Net income 2025 * | -32M -2.93M -234M | EV / Sales 2024 * | 0.81 x |
| Net cash position 2024 * | 36M 3.29M 263M | Net cash position 2025 * | 38M 3.47M 278M | EV / Sales 2025 * | 0.58 x |
| P/E ratio 2024 * |
-1.86
x | P/E ratio 2025 * |
-3.72
x | Employees | - |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 44.36% |
More Fundamentals
* Assessed data
More news
| Managers | Title | Age | Since |
|---|---|---|---|
Anders Hultman
CEO | Chief Executive Officer | 50 | 30/11/18 |
Lars Jakobsson
DFI | Director of Finance/CFO | 67 | - |
Gustav Sten
COO | Chief Operating Officer | - | 31/12/18 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 65 | 31/12/21 | |
| Director/Board Member | 63 | 30/04/21 | |
Clas Runnberg
BRD | Director/Board Member | 72 | 31/12/22 |
AroCell publ AB is a Sweden-based diagnostic Company engaged in the development of markers for determination of cell growth (TK 210) and apoptosis. The Company's principal product candidate, TK-immuno/hem, is a test for monitoring and follow up of blood cancer. The test is based on a patented technology, which have already been evaluated in an early product prototype ELISA method. Apart from that, the Company develops a marker for solid tumor cancer disease. The AroCell cooperates with partners within development, production and sales.
Calendar
02/05/2024
- Q1 2024 Earnings Release
| 1st Jan change | Capi. | |
|---|---|---|
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
